Decitabine/Cedazuridine in the Management of Myelodysplastic Syndrome and Chronic Myelomonocytic Leukemia in Canada.
chronic myelomonocytic leukemia
hypomethylating agents
myelodysplastic syndrome
patient support programs
real-world evidence
treatment patterns
Journal
Current oncology (Toronto, Ont.)
ISSN: 1718-7729
Titre abrégé: Curr Oncol
Pays: Switzerland
ID NLM: 9502503
Informations de publication
Date de publication:
30 Aug 2023
30 Aug 2023
Historique:
received:
23
07
2023
revised:
22
08
2023
accepted:
29
08
2023
medline:
27
9
2023
pubmed:
27
9
2023
entrez:
27
9
2023
Statut:
epublish
Résumé
The management of myelodysplastic syndrome (MDS) and chronic myelomonocytic leukemia (CMML) is limited and remains an unmet need. Decitabine/cedazuridine (DEC-C, ASTX727) is Canada's first and only approved oral hypomethylating agent for MDS and CMML. We characterized the real-world use of DEC-C through a Canadian compassionate use program. Demographic and clinical data from 769 patients enrolled in Taiho Pharma Canada's Patient Support Program were collected and analyzed. These patients represent a collection period from 10 November 2020 to 31 August 2022 with a median age of 76 years. Among 651 patients who started DEC-C, the median treatment duration was 4.2 cycles. The median overall and progression-free survival were 21.6 and 10.7 months, respectively. Among 427 patients who discontinued treatment, the majority (69.5%) stopped due to death (
Identifiants
pubmed: 37754496
pii: curroncol30090581
doi: 10.3390/curroncol30090581
pmc: PMC10528038
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
8005-8018Références
Cancer. 2014 Jun 1;120(11):1670-6
pubmed: 24577838
BMJ Open. 2018 Jul 23;8(7):e019955
pubmed: 30037860
J Clin Oncol. 2006 Aug 20;24(24):3895-903
pubmed: 16921040
J Clin Med. 2021 May 13;10(10):
pubmed: 34068316
Blood Cancer J. 2018 May 24;8(5):47
pubmed: 29795386
Cancer. 2011 Jun 15;117(12):2697-702
pubmed: 21656747
J Appl Lab Med. 2018 Nov 1;3(3):378-383
pubmed: 33636921
J Clin Oncol. 2011 Feb 10;29(5):516-23
pubmed: 21220589
Curr Hematol Malig Rep. 2015 Sep;10(3):272-81
pubmed: 26134527
Cancers (Basel). 2022 Apr 12;14(8):
pubmed: 35454847
Leuk Lymphoma. 2019 Jan;60(1):49-59
pubmed: 29932781
Lancet Haematol. 2019 Apr;6(4):e194-e203
pubmed: 30926081
Blood. 1997 Mar 15;89(6):2079-88
pubmed: 9058730
Am J Hematol. 2020 Jan;95(1):97-115
pubmed: 31736132
Lancet Oncol. 2009 Mar;10(3):223-32
pubmed: 19230772
J Clin Oncol. 2002 May 15;20(10):2429-40
pubmed: 12011120
J Multidiscip Healthc. 2021 Nov 02;14:3063-3071
pubmed: 34754194
Leuk Lymphoma. 2020 May;61(5):1178-1187
pubmed: 31878809
J Natl Compr Canc Netw. 2017 Jan;15(1):60-87
pubmed: 28040720
Br J Haematol. 2015 Aug;170(3):372-83
pubmed: 25907546
Oncotarget. 2017 May 29;8(45):79414-79424
pubmed: 29108320
Cancer Med. 2017 Dec;6(12):2814-2821
pubmed: 29058375
Future Oncol. 2021 Dec;17(36):5163-5175
pubmed: 34636250
Exp Hematol Oncol. 2022 Oct 17;11(1):73
pubmed: 36253799
J Natl Cancer Inst. 2008 Nov 5;100(21):1542-51
pubmed: 18957672
Blood. 2019 Mar 7;133(10):1096-1107
pubmed: 30670446
J Clin Oncol. 2018 Oct 20;36(30):3043-3054
pubmed: 30179565
Blood. 2017 Mar 30;129(13):1753-1762
pubmed: 28096091
Cancer. 2006 Apr 15;106(8):1794-803
pubmed: 16532500
JAMA. 2022 Sep 6;328(9):872-880
pubmed: 36066514
Aging (Albany NY). 2021 Mar 26;13(8):11120-11134
pubmed: 33818418
Blood. 2020 Aug 6;136(6):674-683
pubmed: 32285126
Am J Med. 2012 Jul;125(7 Suppl):S2-5
pubmed: 22735748
Clin Lymphoma Myeloma Leuk. 2022 Sep;22(9):e853-e866
pubmed: 35729009
Support Care Cancer. 2015 Feb;23(2):303-5
pubmed: 25370894
Ann Oncol. 2021 Feb;32(2):142-156
pubmed: 33221366
J Natl Compr Canc Netw. 2011 Jan;9(1):57-63
pubmed: 21233244
Cancer. 2006 May 15;106(10):2087-94
pubmed: 16607649
Ther Adv Hematol. 2012 Dec;3(6):355-73
pubmed: 23606938
Hematology Am Soc Hematol Educ Program. 2020 Dec 4;2020(1):167-174
pubmed: 33275745
Drugs. 2020 Sep;80(13):1373-1378
pubmed: 32860582